{"id":67065,"date":"2026-06-02T13:20:48","date_gmt":"2026-06-02T05:20:48","guid":{"rendered":"https:\/\/flcube.com\/?p=67065"},"modified":"2026-06-02T13:20:49","modified_gmt":"2026-06-02T05:20:49","slug":"changchun-high-new-tech-secures-fda-clearance-for-gensci136-clinical-study-in-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67065","title":{"rendered":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced it has received <strong>Investigational New Drug (IND) clearance<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> to initiate clinical studies of <strong>GenSci136<\/strong>, its Category 1 therapeutic biologic, in patients with <strong>generalized myasthenia gravis (gMG)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>GenSci136 \u2013 Category 1 therapeutic biologic<\/td><\/tr><tr><td><strong>FDA Status<\/strong><\/td><td>IND cleared for clinical investigation<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Generalized myasthenia gravis (gMG)<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>Cleared for clinical studies in immunoglobulin A nephropathy (IgAN) and myasthenia gravis<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> B-cell maturation antigen (BCMA) trimeric fusion protein<\/li>\n\n\n\n<li><strong>Structural Design:<\/strong> Mimics natural BCMA extracellular domain with enhanced binding affinity<\/li>\n\n\n\n<li><strong>Target Ligands:<\/strong> BAFF and APRIL homotrimers and heterotrimers \u2013 key survival factors for B cells and plasma cells<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Potent blocking activity against multiple forms of endogenous ligands, disrupting B lymphocyte survival and plasma cell differentiation<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses humoral immune dysregulation and pathogenic antibody-driven tissue damage in autoimmune diseases<\/li>\n\n\n\n<li><strong>Platform Potential:<\/strong> Applicable across multiple autoimmune conditions characterized by aberrant B-cell activity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-landscape\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>gMG Market Opportunity<\/strong><\/td><td>Estimated 60,000-70,000 gMG patients in the US; global market projected to reach $4.2 billion by 2030<\/td><\/tr><tr><td><strong>Current Treatment Gaps<\/strong><\/td><td>Existing therapies include acetylcholinesterase inhibitors, immunosuppressants, and complement inhibitors; significant unmet need for targeted B-cell modulation<\/td><\/tr><tr><td><strong>BCMA Target Validation<\/strong><\/td><td>BCMA pathway increasingly validated in autoimmune diseases following success in multiple myeloma<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>Trimeric fusion protein design offers potential advantages over monoclonal antibodies targeting single ligands (BAFF or APRIL alone)<\/td><\/tr><tr><td><strong>Chinese Innovation<\/strong><\/td><td>Represents growing trend of Chinese biotechs developing novel mechanisms for global autoimmune markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-development-strategy\" class=\"wp-block-heading\">Strategic Implications &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Market Approach:<\/strong> Simultaneous development in US and China accelerates global regulatory timeline<\/li>\n\n\n\n<li><strong>Platform Expansion:<\/strong> Success in gMG could enable rapid expansion into other autoimmune indications including IgAN, lupus, and rheumatoid arthritis<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> First-in-class mechanism supports premium pricing and significant market share capture<\/li>\n\n\n\n<li><strong>Partnership Attractiveness:<\/strong> Novel mechanism and dual-market progress likely to attract global pharma partnership interest<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Diversified indication strategy reduces dependency on single disease area<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA clearance marks a significant milestone for Changchun High &amp; New Tech, positioning GenSci136 as a potential first-in-class therapy addressing the root cause of antibody-mediated autoimmune diseases through comprehensive BAFF\/APRIL pathway inhibition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory clearances, clinical development plans, and commercial expectations for GenSci136. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-8f257961-ba95-4acf-aa40-0b7638e35abe\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u6ce8\u5c04\u7528GenSci136\u5883\u5916\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8f257961-ba95-4acf-aa40-0b7638e35abe\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,2929,62,1171],"class_list":["post-67065","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67065\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67065\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T05:20:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T05:20:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis\",\"datePublished\":\"2026-06-02T05:20:48+00:00\",\"dateModified\":\"2026-06-02T05:20:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67065#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67065\",\"name\":\"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T05:20:48+00:00\",\"dateModified\":\"2026-06-02T05:20:49+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67065\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67065#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67065","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).","og_url":"https:\/\/flcube.com\/?p=67065","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T05:20:48+00:00","article_modified_time":"2026-06-02T05:20:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67065#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67065"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis","datePublished":"2026-06-02T05:20:48+00:00","dateModified":"2026-06-02T05:20:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67065"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67065#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67065","url":"https:\/\/flcube.com\/?p=67065","name":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T05:20:48+00:00","dateModified":"2026-06-02T05:20:49+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical studies of GenSci136, its Category 1 therapeutic biologic, in patients with generalized myasthenia gravis (gMG).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67065#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67065"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67065#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67065"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67065\/revisions"}],"predecessor-version":[{"id":67067,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67065\/revisions\/67067"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}